Cargando…
Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer
The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has dramatically evolved. Monotherapy androgen deprivation therapy (ADT) with testosterone suppression alone is no longer the standard of care as multiple global phase 3 trials of different combinatorial strategies have...
Autores principales: | Jazayeri, Seyed Behzad, Cooley, Lauren Folgosa, Srivastava, Abhishek, Shore, Neal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523347/ https://www.ncbi.nlm.nih.gov/pubmed/36186607 http://dx.doi.org/10.1016/j.euros.2022.05.015 |
Ejemplares similares
-
Clinically Significant Prostate Cancer Diagnosis Without Histological Proof: A Possibility in the Prostate-specific Membrane Antigen Era?
por: Heetman, Joris G., et al.
Publicado: (2022) -
Superfast Magnetic Resonance Imaging-based Diagnostic Pathway for Prostate Cancer
por: Paulino Pereira, Leonor Jane, et al.
Publicado: (2022) -
Magnetic Resonance Imaging–guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies
por: Giganti, Francesco, et al.
Publicado: (2022) -
Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
por: Raggi, Daniele, et al.
Publicado: (2021) -
Is Artificial Intelligence Replacing Our Radiology Stars? Not Yet!
por: Cacciamani, Giovanni E., et al.
Publicado: (2022)